Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...

Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking ...

Conditions are getting a bit more challenging for the drugmaker.

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...

INDIANAPOLIS -- Eli Lilly dialed back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales ...

AP Health Writer (AP) — Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter ...

Indianapolis, Indiana-based Eli Lilly and Company (LLY ... author and do not necessarily reflect those of Nasdaq, Inc. With headquarters in the heart of Chicago's financial district, Barchart ...

Sales of Eli Lilly’s (LLY) blockbuster weight loss drug Zepbound are still booming, but just not at the level Wall Street was ...

BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations INDIANAPOLIS -- Eli Lilly is dialing ...